{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:29:26Z","timestamp":1790962166264,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03744-z","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T05:02:22Z","timestamp":1724043742000},"page":"1773-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of SLC6A2 and CYP2D6 polymorphisms\u2019 effects on atomoxetine treatment in attention deficit and hyperactivity disorder"],"prefix":"10.1007","volume":"80","author":[{"given":"Ismail Hasan","family":"Kole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beste","family":"Yurdacan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Alemdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"1","key":"3744_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","volume":"49","author":"N Salari","year":"2023","unstructured":"Salari N et al (2023) The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. Ital J Pediatr 49(1):48","journal-title":"Ital J Pediatr"},{"issue":"2","key":"3744_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1615\/CritRevNeurobiol.v16.i12.130","volume":"16","author":"E Carboni","year":"2004","unstructured":"Carboni E, Silvagni A (2004) Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol 16(2):121\u2013128","journal-title":"Crit Rev Neurobiol"},{"key":"3744_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/3-540-29784-7_20","volume-title":"Neurotransmitter Transporters","author":"H B\u00f6nisch","year":"2006","unstructured":"B\u00f6nisch H, Br\u00fcss M (2006) The norepinephrine transporter in physiology and disease. Neurotransmitter Transporters. Springer, pp 485\u2013524"},{"issue":"2","key":"3744_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1523\/JNEUROSCI.22-02-00389.2002","volume":"22","author":"JA Mor\u00f3n","year":"2002","unstructured":"Mor\u00f3n JA et al (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22(2):389\u2013395","journal-title":"J Neurosci"},{"key":"3744_CR5","unstructured":"Eli Lilly and Company (2022) Strattera\u00ae (atomoxetine hydrochloride)\u2014prescribing information. Available online: https:\/\/pi.lilly.com\/us\/strattera-pi.pdf. Accessed\u00a0 14 Aug 2024"},{"issue":"5","key":"3744_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1089\/cap.2020.0178","volume":"31","author":"NM Shaker","year":"2021","unstructured":"Shaker NM et al (2021) Atomoxetine in attention-deficit\/hyperactivity disorder in children with and without comorbid mood disorders. J Child Adolescent Psychopharmacol 31(5):332\u2013341","journal-title":"J Child Adolescent Psychopharmacol"},{"key":"3744_CR7","doi-asserted-by":"publisher","unstructured":"Childress AC (2015) A critical appraisal of atomoxetine in the management of ADHD.\u00a0Ther Clin Risk Manag\u00a012:27\u201339. https:\/\/doi.org\/10.2147\/TCRM.S59270","DOI":"10.2147\/TCRM.S59270"},{"issue":"7","key":"3744_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","volume":"46","author":"S Pliszka","year":"2007","unstructured":"Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894\u2013921","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3744_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S115707","volume":"13","author":"DB Clemow","year":"2017","unstructured":"Clemow DB et al (2017) A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatric Dis Treatment 13:357\u201371","journal-title":"Neuropsychiatric Dis Treatment"},{"issue":"5","key":"3744_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","volume":"48","author":"JH Newcorn","year":"2009","unstructured":"Newcorn JH et al (2009) Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the integrated data exploratory analysis (IDEA) study. J Am Acad Child Adolescent Psychiatry 48(5):511\u2013518","journal-title":"J Am Acad Child Adolescent Psychiatry"},{"issue":"1","key":"3744_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/dmd.31.1.98","volume":"31","author":"JM Sauer","year":"2003","unstructured":"Sauer JM et al (2003) Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 31(1):98\u2013107","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3744_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/01.chi.0000246056.83791.b6","volume":"46","author":"D Michelson","year":"2007","unstructured":"Michelson D et al (2007) CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 46(2):242\u2013251","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"3744_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euroneuro.2007.06.002","volume":"18","author":"PT Trzepacz","year":"2008","unstructured":"Trzepacz PT et al (2008) CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 18(2):79\u201386","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"3744_CR14","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/npp.2009.39","volume":"34","author":"N Ramoz","year":"2009","unstructured":"Ramoz N et al (2009) A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). J Neuropsychopharmacol 34(9):2135\u20132142","journal-title":"J Neuropsychopharmacol"},{"key":"3744_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12402-009-0012-4","volume":"1","author":"P Hazell","year":"2009","unstructured":"Hazell P et al (2009) Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder. ADHD Atten Def Hyp Disord 1:201\u2013210","journal-title":"ADHD Atten Def Hyp Disord"},{"issue":"7","key":"3744_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00702-012-0955-z","volume":"120","author":"L Yang","year":"2013","unstructured":"Yang L et al (2013) Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm (Vienna) 120(7):1127\u20131133","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"3744_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/02698811211015245","volume":"36","author":"MK Gul","year":"2022","unstructured":"Gul MK et al (2022) Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: from response to side effects in children with ADHD. J Psychopharmacol 36(6):715\u2013722","journal-title":"J Psychopharmacol"},{"issue":"4","key":"3744_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/10870547231214988","volume":"28","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W, Tsuda H (2024) The dose-response relationship of atomoxetine for the treatment of children with ADHD: a systematic review and dose-response meta-analysis of double-blind randomized placebo-controlled trials. J Atten Disord 28(4):431\u2013438","journal-title":"J Atten Disord"},{"issue":"27","key":"3744_CR19","doi-asserted-by":"publisher","first-page":"e26552","DOI":"10.1097\/MD.0000000000026552","volume":"100","author":"A Sugimoto","year":"2021","unstructured":"Sugimoto A et al (2021) The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit\/hyperactivity disorder: a non-randomized prospective interventional study. Medicine 100(27):e26552","journal-title":"Medicine"},{"issue":"3","key":"3744_CR20","first-page":"349","volume":"79","author":"D Fu","year":"2023","unstructured":"Fu D et al (2023) Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. Eur J Clin Pharmacol 79(3):349\u2013370","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3744_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41398-024-02859-2","volume":"14","author":"HL Guo","year":"2024","unstructured":"Guo HL et al (2024) Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together. Transl Psychiatry 14(1):151","journal-title":"Transl Psychiatry"},{"issue":"2","key":"3744_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/medicina58020285","volume":"58","author":"A Norkeviciene","year":"2022","unstructured":"Norkeviciene A et al (2022) A systematic review of candidate genes for major depression. Medicina 58(2):285","journal-title":"Medicina"},{"key":"3744_CR23","doi-asserted-by":"publisher","first-page":"110227","DOI":"10.1016\/j.pnpbp.2020.110227","volume":"107","author":"SY Kim","year":"2021","unstructured":"Kim SY et al (2021) Association between genetic variants of the norepinephrine transporter gene (SLC6A2) and bipolar I disorder. Progress in Neuro-Psychopharmacol Biol Psychiatry 107:110227","journal-title":"Progress in Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"3744_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jcpp.12278","volume":"56","author":"L Liu","year":"2015","unstructured":"Liu L et al (2015) The possible involvement of genetic variants of NET 1 in the etiology of attention-deficit\/hyperactivity disorder comorbid with oppositional defiant disorder. J Child Psychol Psychiatry 56(1):58\u201366","journal-title":"J Child Psychol Psychiatry"},{"key":"3744_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00702-012-0955-z","volume":"120","author":"L Yang","year":"2013","unstructured":"Yang L et al (2013) Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transmission 120:1127\u20131133","journal-title":"J Neural Transmission"},{"issue":"1","key":"3744_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cpt.1409","volume":"106","author":"JT Brown","year":"2019","unstructured":"Brown JT et al (2019) Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP) 2D6 genotype and atomoxetine therapy. Clin Pharma Therapeutics 106(1):94\u2013102","journal-title":"Clin Pharma Therapeutics"},{"key":"3744_CR27","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs"},{"issue":"4","key":"3744_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/jcm8040461","volume":"8","author":"M Weiss","year":"2019","unstructured":"Weiss M et al (2019) Characteristics of ADHD symptom response\/remission in a clinical trial of methylphenidate extended release. J Clin Med 8(4):461","journal-title":"J Clin Med"},{"issue":"7","key":"3744_CR29","first-page":"24","volume":"59","author":"CK Conners","year":"1998","unstructured":"Conners CK (1998) Rating scales in attention-deficit\/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 59(7):24\u201330","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"3744_CR30","first-page":"50","volume":"10","author":"G K\u0131l\u0131\u00e7","year":"2003","unstructured":"K\u0131l\u0131\u00e7 G, Sener S (2003) Dikkat eksikli\u011fi hiperaktivite bozuklu\u011fu alt gruplar\u0131nda Conners \u00f6\u011fretmen ve anababa \u00f6l\u00e7eklerinin ay\u0131r\u0131c\u0131 \u00f6zellikleri. \u00c7ocuk ve Gen\u00e7lik Ruh Sa\u011fl\u0131\u011f\u0131 Dergisi 10(2):50\u201357","journal-title":"\u00c7ocuk ve Gen\u00e7lik Ruh Sa\u011fl\u0131\u011f\u0131 Dergisi"},{"key":"3744_CR31","volume-title":"Conners anababa derecelendirme \u00f6l\u00e7e\u011fi uyarlama \u00e7al\u0131\u015fmas\u0131, in X","author":"CS Dereboy","year":"1998","unstructured":"Dereboy CS et al (1998) Conners anababa derecelendirme \u00f6l\u00e7e\u011fi uyarlama \u00e7al\u0131\u015fmas\u0131, in X. Ulusal Psikoloji Kongresi, Ankara"},{"issue":"1","key":"3744_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2008.172","volume":"85","author":"M Bijl","year":"2009","unstructured":"Bijl M et al (2009) Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in \u03b2-blocker users. J Clin Pharma Therapeutics 85(1):45\u201350","journal-title":"J Clin Pharma Therapeutics"},{"key":"3744_CR33","doi-asserted-by":"publisher","unstructured":"Bagheri A et al (2015) Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.\u00a0Drug Des Devel Ther 2627\u20132634. https:\/\/doi.org\/10.2147\/DDDT.S79709","DOI":"10.2147\/DDDT.S79709"},{"issue":"6","key":"3744_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/cpt.319","volume":"99","author":"JT Brown","year":"2016","unstructured":"Brown JT et al (2016) Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther 99(6):642\u2013650","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3744_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.pbb.2011.01.020","volume":"99","author":"AF Arnsten","year":"2011","unstructured":"Arnsten AF, Pliszka SR (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit\/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 99(2):211\u2013216","journal-title":"Pharmacol Biochem Behav"},{"issue":"50","key":"3744_CR36","doi-asserted-by":"publisher","first-page":"19164","DOI":"10.1073\/pnas.0510836103","volume":"103","author":"C-H Kim","year":"2006","unstructured":"Kim C-H et al (2006) A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. J Proc Natl Acad of Sci 103(50):19164\u201319169","journal-title":"J Proc Natl Acad of Sci"},{"issue":"9","key":"3744_CR37","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/01.chi.0000131134.63368.46","volume":"43","author":"L Yang","year":"2004","unstructured":"Yang L et al (2004) Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43(9):1154\u20131158","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"3744_CR38","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.mp.4002090","volume":"13","author":"J Kim","year":"2008","unstructured":"Kim J et al (2008) Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. J Molecular psychiatry 13(6):624\u2013630","journal-title":"J Molecular psychiatry"},{"issue":"10","key":"3744_CR39","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.mp.4001869","volume":"11","author":"K Brookes","year":"2006","unstructured":"Brookes K et al (2006) The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11(10):934\u2013953","journal-title":"Mol Psychiatry"},{"key":"3744_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mgene.2016.11.007","volume":"11","author":"A Ray","year":"2017","unstructured":"Ray A et al (2017) Dimorphic association of dopaminergic transporter gene variants with treatment outcome: pilot study in Indian ADHD probands. J Meta Gene 11:64\u201369","journal-title":"J Meta Gene"},{"issue":"1","key":"3744_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/cap.2020.0058","volume":"31","author":"SA Jallaq","year":"2021","unstructured":"Jallaq SA et al (2021) CYP2D6 phenotype influences aripiprazole tolerability in pediatric patients with mood disorders. J Child Adolesc Psychopharmacol 31(1):56\u201362","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3744_CR42","unstructured":"Dean L (2012) Atomoxetine therapy and CYP2D6 genotype. In: Medical genetics summaries. National Center for Biotechnology Information (US), Bethesda (MD)"},{"key":"3744_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ygyno.2022.10.021","volume":"168","author":"D Mysona","year":"2023","unstructured":"Mysona D et al (2023) Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with taxane-based chemotherapy. Gynecol Oncol 168:114\u2013118","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3744_CR44","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/mp.2017.234","volume":"23","author":"NM Myer","year":"2018","unstructured":"Myer NM, Boland JR, Faraone SV (2018) Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 23(9):1929\u20131936","journal-title":"Mol Psychiatry"},{"key":"3744_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-9081-8-22","volume":"8","author":"S Park","year":"2012","unstructured":"Park S et al (2012) Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder. Behav Brain Functions 8:1\u20138","journal-title":"Behav Brain Functions"},{"issue":"5","key":"3744_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/cap.2011.0076","volume":"22","author":"SB Hong","year":"2012","unstructured":"Hong SB et al (2012) Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit\/hyperactivity disorder: is there an interaction? J Child Adolescent Psychopharmacol 22(5):343\u2013352","journal-title":"J Child Adolescent Psychopharmacol"},{"key":"3744_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-9081-6-57","volume":"6","author":"BN Kim","year":"2010","unstructured":"Kim BN et al (2010) Possible association of norepinephrine transporter-3081 (A\/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behav Brain Funct 6:1\u20138","journal-title":"Behav Brain Funct"},{"key":"3744_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pnpbp.2018.01.013","volume":"84","author":"N Angyal","year":"2018","unstructured":"Angyal N et al (2018) Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients. Progress in Neuro-Psychopharmacol Biol Psychiatry 84:122\u2013128","journal-title":"Progress in Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"3744_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/YIC.0b013e32834152d1","volume":"26","author":"J Song","year":"2011","unstructured":"Song J et al (2011) Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol 26(2):107\u2013113","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"3744_CR50","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/CHI.0b013e3181bc72e3","volume":"48","author":"JJ McGough","year":"2009","unstructured":"McGough JJ et al (2009) A candidate gene analysis of methylphenidate response in attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 48(12):1155\u20131164","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"3744_CR51","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/s41598-017-10912-y","volume":"7","author":"CI Gomez-Sanchez","year":"2017","unstructured":"Gomez-Sanchez CI et al (2017) Pharmacogenetics of methylphenidate in childhood attention-deficit\/hyperactivity disorder: long-term effects. Sci Rep 7(1):10391","journal-title":"Sci Rep"},{"issue":"3","key":"3744_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/JCP.0b013e31828f9fc3","volume":"33","author":"BN Kim","year":"2013","unstructured":"Kim BN et al (2013) Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol 33(3):356\u2013362","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"3744_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/cap.2015.0137","volume":"26","author":"G Yu","year":"2016","unstructured":"Yu G et al (2016) Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol 26(4):314\u2013326","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"3744_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/JCP.0b013e3182a608a2","volume":"34","author":"CI Choi","year":"2014","unstructured":"Choi CI et al (2014) Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 34(1):139\u2013142","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"3744_CR55","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00228-022-03321-2","volume":"78","author":"E Demirci","year":"2022","unstructured":"Demirci E et al (2022) A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels. Eur J Clin Pharmacol 78(7):1095\u20131104","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03744-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T03:02:10Z","timestamp":1728270130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03744-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03744-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4402227\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki after receiving approval from the local ethics committee of Bursa Uludag University (Decision no: 2016\u201311\/24). Prior to participating, informed consent was obtained from all patients for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}